Our Mission
Connect the knowledge, technologies, professionals and infrastructure required to advance regenerative medicine responsibly and expand its reach globally.
About RMTG
An integrated regenerative medicine company
Regenerative Medical Technology Group (OTC: RMTG) connects biotechnology, physician education, clinical application and global provider networks through one operating platform — Global Stem Cells Group and its specialized businesses.
Who we are
Building the infrastructure of regenerative medicine
RMTG is a Publicly Traded Company built around a single idea: that education, biotechnology, clinical application and distribution perform better when they operate as one connected platform rather than as separate businesses.
Through its wholly owned operating subsidiary, Global Stem Cells Group, RMTG brings together specialized businesses spanning physician education, biologics and laboratory capabilities, flagship clinical infrastructure and an international provider-network model.
Together, these businesses are designed to advance regenerative medicine from scientific knowledge to responsible, real-world application.
Our Vision
A connected regenerative medicine marketplace in which scientific innovation, education, biotechnology, clinical expertise and responsible commercialization work together.
Our Principles
Scientific integrity, quality, education, integration and global collaboration guide how the platform is built and operated.
Long-Term Value
Our corporate strategy is focused on developing sustainable operating businesses capable of creating long-term shareholder value.
Leadership
Built around operations and growth
Dave Christensen
CEO and President
Dave Christensen is the CEO and President of Regenerative Medical Technology Group Inc. ($RMTG), a publicly traded biotechnology company with Global Stem Cells Group (GSCG) as its wholly owned operating subsidiary.
With over 36 years of experience helping companies go from good to great, Dave is a recognized expert in global strategy deployment — a former CEO and EVP of Enterprise Technology Consulting and a Lean Six Sigma Black Belt specializing in Hoshin Kanri (“policy management”).
He has held multiple C-level positions, led major M&A transactions and completed an IPO with a NASDAQ launch. A BYU graduate in Organizational Behavior, he has worked with Compaq, HP, Qualcomm, Walmart International, Carlyle-Rexnord and Verifone across technology, supply chain, payments and logistics.
- 36+ years’ experience across 55 countries
- Multilingual — English, Spanish & Portuguese
- Walmart International — logistics to technology
- Qualcomm worldwide logistics and operations
- Compaq / HP worldwide supply chain strategy
- 17 years with Carlyle and other private equity
- 8 years fintech (Hypercom / Verifone)
- IPO on NASDAQ · 2 blockchain patents
Benito Novas
Founder & CEO, Global Stem Cells Group
Benito Novas is the founder and CEO of Global Stem Cells Group (GSCG), RMTG’s wholly owned operating subsidiary, and a visionary entrepreneur driving innovation in regenerative medicine across five continents.
Since founding GSCG in 2010, he has grown it from a startup into a comprehensive enterprise spanning physician education, biotechnology and cGMP manufacturing, flagship clinical infrastructure and an international provider network. Earlier he co-founded U.S. medical clinics and launched one of the first consultancies for cash-based medical practices.
A recognized thought leader, Benito has trained thousands of physicians, keynoted the ISSCA World Congress and received an Honorary Doctorate (Doctor Honoris Causa) in Health Sciences in Medellín, Colombia for advancing regenerative medicine and medical education.
- Founder & CEO of Global Stem Cells Group (2010)
- Regenerative medicine leadership across 5 continents
- Provider network spanning 30+ international cities
- Thousands of physicians trained worldwide
- Keynote speaker & organizer, ISSCA World Congress
- Honorary Doctorate (Doctor Honoris Causa), Colombia
- Pioneer of cash-based medical practice marketing
- Co-founder of multiple U.S. medical clinics
Board of Directors and corporate officers to be listed per SEC-verified composition. Titles reconcile to the company’s latest filing.
History
A transformation years in the making
From a legacy small cap to a vertically integrated regenerative-medicine company, executed through Global Stem Cells Group (GSCG).
- 011999
Incorporated
Founded in Nevada.
- 02Aug 2021
GSCG acquisition completed
New name, logo and share structure announced; pivot to regenerative medicine.
- 03Oct 2024
Becomes RMTG
Name change completed and the company begins trading as RMTG on the OTC market.
- 042024–2025
Vertical model
Clinics, Cellgenic manufacturing, ISSCA training and equipment unified under GSCG.
- 05Q2 2025
Category leader
Operating across 30+ countries with a hybrid B2B/B2C revenue engine.
- 06Q1 2026
Biologics manufacturing
Full-scale biologics manufacturing in both Cancún, Mexico and Buenos Aires, Argentina.
Source: SEC EDGAR filings & press releases and Company Outlook. Specific dates and details are set out in the company's public filings.
Quality & compliance
Quality-controlled manufacturing, certified physician training and documented clinical protocols underpin how the businesses operate.
Global collaboration
The RMTG ecosystem connects physicians, scientists, distributors and strategic partners across international markets.
Public accountability
As an SEC reporting company, RMTG communicates through public filings and disclosures on behalf of shareholders.
Corporate snapshot
The essentials
Corporate details are provided for reference. Investors should rely on the company’s current SEC filings for authoritative information.
- Public listing
- OTC: RMTG
- Operating subsidiary
- Global Stem Cells Group
- Operating businesses
- ISSCA · Cellgenic · Cellular Institute · Stem Cell Center
- Reporting status
- SEC reporting company